Martin M Meremikwu1, Uduak Okomo. 1. Department of Paediatrics, College of Medical Sciences, University of Calabar, Calabar, Nigeria.
Abstract
INTRODUCTION: Sickle cell disease causes chronic haemolytic anaemia, dactylitis, and painful acute crises. It also increases the risk of stroke, organ damage, bacterial infections, and complications of blood transfusion. In sub-Saharan Africa, up to one third of adults are carriers of the defective sickle cell gene, and 1% to 2% of babies are born with the disease. METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical question: What are the effects of pharmaceutical interventions to prevent sickle cell crisis and other acute complications in people with sickle cell disease? We searched: Medline, Embase, The Cochrane Library, and other important databases up to January 2015 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview). RESULTS: At this update, searching of electronic databases retrieved 369 studies. After deduplication and removal of conference abstracts, 136 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 99 studies and the further review of 37 full publications. Of the 37 full articles evaluated, three already included systematic reviews were updated, two systematic reviews, two RCTs, and one subsequent RCT were added at this update. We performed a GRADE evaluation for 12 PICO combinations. CONCLUSIONS: In this systematic overview, we categorised the efficacy for five interventions based on information about the effectiveness and safety of antibiotic prophylaxis in children aged under 5 years, antibiotic prophylaxis in children aged 5 years or older, hydroxyurea, malaria chemoprophylaxis, and pneumococcal vaccines.
INTRODUCTION: Sickle cell disease causes chronic haemolytic anaemia, dactylitis, and painful acute crises. It also increases the risk of stroke, organ damage, bacterial infections, and complications of blood transfusion. In sub-Saharan Africa, up to one third of adults are carriers of the defective sickle cell gene, and 1% to 2% of babies are born with the disease. METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical question: What are the effects of pharmaceutical interventions to prevent sickle cell crisis and other acute complications in people with sickle cell disease? We searched: Medline, Embase, The Cochrane Library, and other important databases up to January 2015 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview). RESULTS: At this update, searching of electronic databases retrieved 369 studies. After deduplication and removal of conference abstracts, 136 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 99 studies and the further review of 37 full publications. Of the 37 full articles evaluated, three already included systematic reviews were updated, two systematic reviews, two RCTs, and one subsequent RCT were added at this update. We performed a GRADE evaluation for 12 PICO combinations. CONCLUSIONS: In this systematic overview, we categorised the efficacy for five interventions based on information about the effectiveness and safety of antibiotic prophylaxis in children aged under 5 years, antibiotic prophylaxis in children aged 5 years or older, hydroxyurea, malaria chemoprophylaxis, and pneumococcal vaccines.
Authors: G M Woods; J H Jorgensen; M A Waclawiw; C Reid; W Wang; C H Pegelow; Z R Rogers; R V Iyer; C T Holbrook; T R Kinney; E Vichinsky; M R DeBaun; N J Grossman; M D Thomas; J M Falletta Journal: J Pediatr Hematol Oncol Date: 1997 Jul-Aug Impact factor: 1.289
Authors: Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson Journal: Lancet Date: 2011-05-14 Impact factor: 79.321
Authors: P Harmatz; E Butensky; K Quirolo; R Williams; L Ferrell; T Moyer; D Golden; L Neumayr; E Vichinsky Journal: Blood Date: 2000-07-01 Impact factor: 22.113
Authors: J M Falletta; G M Woods; J I Verter; G R Buchanan; C H Pegelow; R V Iyer; S T Miller; C T Holbrook; T R Kinney; E Vichinsky Journal: J Pediatr Date: 1995-11 Impact factor: 4.406
Authors: Russell E Ware; Barry R Davis; William H Schultz; R Clark Brown; Banu Aygun; Sharada Sarnaik; Isaac Odame; Beng Fuh; Alex George; William Owen; Lori Luchtman-Jones; Zora R Rogers; Lee Hilliard; Cynthia Gauger; Connie Piccone; Margaret T Lee; Janet L Kwiatkowski; Sherron Jackson; Scott T Miller; Carla Roberts; Matthew M Heeney; Theodosia A Kalfa; Stephen Nelson; Hamayun Imran; Kerri Nottage; Ofelia Alvarez; Melissa Rhodes; Alexis A Thompson; Jennifer A Rothman; Kathleen J Helton; Donna Roberts; Jamie Coleman; Melanie J Bonner; Abdullah Kutlar; Niren Patel; John Wood; Linda Piller; Peng Wei; Judy Luden; Nicole A Mortier; Susan E Stuber; Naomi L C Luban; Alan R Cohen; Sara Pressel; Robert J Adams Journal: Lancet Date: 2015-12-06 Impact factor: 79.321
Authors: Manix Ilunga Banza; Jules Panda Mulefu; Lire Ipani Lire; Yannick Tietie Ben N'dwala; Israel Badypwyla Tshiamala; Vincent de Paul Kaoma Cabala Journal: Pan Afr Med J Date: 2019-07-26
Authors: Ibrahim Khamees; Fateen Ata; Hassan Choudry; Ashraf T Soliman; Vincenzo De Sanctis; Mohamed A Yassin Journal: J Transl Med Date: 2021-06-16 Impact factor: 5.531